ICU Medical, Inc. (NASDAQ:ICUI) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $192.80.

A number of brokerages have recently commented on ICUI. Needham & Company LLC boosted their price target on ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a report on Friday, August 7th. Raymond James Financial restated a “strong-buy” rating and issued a $200.00 target price on shares of ICU Medical in a research note on Friday, August 7th. Wall Street Zen raised ICU Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Weiss Ratings raised shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Finally, Piper Sandler lifted their price objective on shares of ICU Medical from $163.00 to $195.00 and gave the company an “overweight” rating in a report on Friday, August 7th.

Insiders Place Their Bets

In other ICU Medical news, Director Elisha Finney sold 378 shares of ICU Medical stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total value of $68,977.44. Following the sale, the director directly owned 4,871 shares in the company, valued at approximately $888,860.08. The trade was a 7.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Christian B. Voigtlander sold 8,929 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $182.93, for a total transaction of $1,633,381.97. Following the sale, the chief operating officer directly owned 37,377 shares in the company, valued at $6,837,374.61. This trade represents a 19.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 21,830 shares of company stock valued at $3,905,003 in the last quarter. Company insiders own 2.10% of the company’s stock.

Institutional Trading of ICU Medical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Allworth Financial LP acquired a new position in ICU Medical during the second quarter valued at approximately $26,000. Hilton Head Capital Partners LLC acquired a new position in shares of ICU Medical during the 4th quarter worth approximately $32,000. Public Employees Retirement System of Ohio bought a new stake in shares of ICU Medical during the 2nd quarter worth approximately $51,000. Covestor Ltd raised its stake in shares of ICU Medical by 22.1% during the 4th quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 126 shares in the last quarter. Finally, Strs Ohio boosted its holdings in shares of ICU Medical by 60.0% in the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after buying an additional 300 shares during the last quarter. Institutional investors own 96.10% of the company’s stock.

ICU Medical Stock Up 0.1%

ICU Medical stock opened at $161.00 on Thursday. The company has a 50 day moving average of $168.28 and a 200-day moving average of $145.14. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56. ICU Medical has a twelve month low of $112.50 and a twelve month high of $192.85. The stock has a market capitalization of $4.02 billion, a PE ratio of 136.44, a price-to-earnings-growth ratio of 2.03 and a beta of 0.75.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, beating the consensus estimate of $1.91 by $0.46. The business had revenue of $547.88 million for the quarter, compared to analysts’ expectations of $533.44 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The firm’s revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.10 EPS. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, equities research analysts anticipate that ICU Medical will post 7.19 EPS for the current fiscal year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.